Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to $97000.0.

  • Enanta Pharmaceuticals' Gains from Investment Securities fell 8226.69% to $97000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $1.6 million, marking a year-over-year decrease of 3323.77%. This contributed to the annual value of $5.8 million for FY2025, which is 1109.18% up from last year.
  • According to the latest figures from Q4 2025, Enanta Pharmaceuticals' Gains from Investment Securities is $97000.0, which was down 8226.69% from $6.0 million recorded in Q2 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Gains from Investment Securities peaked at $15.6 million during Q4 2021, and registered a low of $83000.0 during Q3 2023.
  • For the 5-year period, Enanta Pharmaceuticals' Gains from Investment Securities averaged around $3.8 million, with its median value being $4.0 million (2022).
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Gains from Investment Securities plummeted by 9491.69% in 2021, and later skyrocketed by 108674.7% in 2024.
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' Gains from Investment Securities stood at $15.6 million in 2021, then tumbled by 94.7% to $825000.0 in 2022, then surged by 531.88% to $5.2 million in 2023, then crashed by 89.51% to $547000.0 in 2024, then plummeted by 82.27% to $97000.0 in 2025.
  • Its Gains from Investment Securities was $97000.0 in Q4 2025, compared to $6.0 million in Q2 2025 and $6.0 million in Q1 2025.